GSK’s (GSK) “Buy” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their buy rating on shares of GSK (LON:GSK) in a research note released on Wednesday morning, MarketBeat.com reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,950 ($24.27) price objective on the stock.

A number of other research firms have also commented on GSK. Barclays reaffirmed an equal weight rating and set a GBX 1,725 ($21.47) price target on shares of GSK in a research report on Monday, April 8th. Shore Capital reaffirmed a buy rating on shares of GSK in a research note on Thursday, March 7th. Finally, Berenberg Bank lifted their price target on shares of GSK from GBX 1,650 ($20.54) to GBX 1,820 ($22.66) and gave the company a buy rating in a report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Hold and an average target price of GBX 1,630.63 ($20.30).

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,599 ($19.91) on Wednesday. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82. The company has a 50-day moving average price of GBX 1,661.17 and a 200-day moving average price of GBX 1,546.13. The company has a market cap of £65.40 billion, a price-to-earnings ratio of 1,332.50, a price-to-earnings-growth ratio of 1.09 and a beta of 0.27. GSK has a 12 month low of GBX 1,302.60 ($16.22) and a 12 month high of GBX 1,719.80 ($21.41).

GSK Increases Dividend

The company also recently disclosed a dividend, which was paid on Thursday, April 11th. Shareholders of record on Thursday, February 22nd were given a dividend of GBX 16 ($0.20) per share. The ex-dividend date of this dividend was Thursday, February 22nd. This represents a yield of 1.04%. This is a positive change from GSK’s previous dividend of $14.00. GSK’s dividend payout ratio (DPR) is currently 5,333.33%.

Insider Activity

In other GSK news, insider Julie Brown purchased 19,360 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was bought at an average cost of GBX 1,583 ($19.71) per share, for a total transaction of £306,468.80 ($381,512.26). In related news, insider Julie Brown purchased 19,360 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were bought at an average price of GBX 1,583 ($19.71) per share, for a total transaction of £306,468.80 ($381,512.26). Also, insider Urs Rohner acquired 434 shares of GSK stock in a transaction that occurred on Wednesday, March 20th. The shares were bought at an average cost of GBX 1,662 ($20.69) per share, with a total value of £7,213.08 ($8,979.31). In the last 90 days, insiders have acquired 19,802 shares of company stock worth $31,381,484. Corporate insiders own 1.71% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.